Characterization, in vitro cytotoxicity and cellular accumulation of paclitaxel-loaded lipid nano-emulsions

References

• Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res 1994; 11: 206–212
   PubMed Web of Science ®Google Scholar
• Christopher AJ, Fennell TRFW. Determination of phosphorus in organic compounds on the centimilligram scale. Microchem J 1967; 12: 593–605
   Web of Science ®Google Scholar
• Constantinides PP, Lambert KJ, Tustian AK, Schneider B, Lalji S, Ma W, Wentzel B, Kessler D, Worah D, Quay SC. Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res 2000; 17: 175–182
   PubMed Web of Science ®Google Scholar
• Dordunoo SK, Burt HM. Solubility and stability of taxol: Effects of buffers and cyclodextrins. Int J Pharm 1996; 133: 191–201
   Web of Science ®Google Scholar
• Han J, Davis SS, Papandreou C, Melia CD, Washington C. Design and evaluation of an emulsion vehicle for paclitaxel. I. Physicochemical properties and plasma stability. Pharm Res 2004; 21: 1573–1580
   Google Scholar
• Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6: 559–593
   PubMed Web of Science ®Google Scholar
• Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253–266
   PubMed Web of Science ®Google Scholar
• Kan P, Chen ZB, Lee CJ, Chu IM. Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system. J Contr Rel 1999; 58: 271–278
   PubMed Web of Science ®Google Scholar
• Lee J, Lee SC, Acharya G, Chang C-J, Park K. Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm Res 2003; 20: 1022–1030
   PubMed Web of Science ®Google Scholar
• Liggins RT, Hunter WL, Burt HM. Solid-state characterization of paclitaxel. J Pharm Sci 1997; 86: 1458–1463
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Lundberg BB. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (taxol). J Pharm Pharmacol 1997; 49: 16–21
   PubMed Web of Science ®Google Scholar
• Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev 1991; 6: 181–202
   Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Contr Rel 2000; 65: 271–284
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387–6392
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y, Tokuuye K. Preparation of gadolinium-containing emulsions stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy. Chem Pharm Bull 1999; 47: 203–208
   Web of Science ®Google Scholar
• Mo Y, Lim LY. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Contr Rel 2005; 107: 30–42
   PubMed Web of Science ®Google Scholar
• Seki J, Sasaki H, Doi M, Yoshikawa H, Takahashi Y, Yamane S, Fukui H, Sonoke S, Yamamoto H, Hirose M, et al. Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration. IV. J Contr Rel 1994; 28: 352–353
   Web of Science ®Google Scholar
• Sharma A, Straubinger RM. Novel taxol formulations: Preparation and characterization of taxol-containing liposomes. Pharm Res 1994; 11: 889–896
   PubMed Web of Science ®Google Scholar
• Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, Yokoyama T. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 2009; 278: 88–96
   PubMed Web of Science ®Google Scholar
• Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N, Yokoyama T. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemo Pharmacol 2006; 58: 785–793
   PubMed Web of Science ®Google Scholar
• Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 2002; 25: 771–778
   PubMed Web of Science ®Google Scholar
• Takegami S, Kitamura K, Kawada H, Matsumoto Y, Kitade T, Ishida H, Nagata C. Preparation and characterization of a new lipid nano-emulsion containing two cosurfactants, sodium palmitate for droplet size reduction and sucrose palmitate for stability enhancement. Chem Pharm Bull 2008; 56: 1097–1102
   PubMed Web of Science ®Google Scholar
• Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents, VI: Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325–2327
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from Taxol. J Clin Oncol 1990; 8: 1263–1268
   PubMed Web of Science ®Google Scholar
• Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastructure Res 1970; 31: 125–150
   PubMedGoogle Scholar
• Yegin BA, Benoit JP, Lamprecht A. Paclitaxel-loaded lipid nanoparticles prepared by solvent injection or ultrasound emulsification. Drug Devel Ind Pharm 2006; 32: 1089–1094
   PubMed Web of Science ®Google Scholar
• Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterization of a novel Cremophor® EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 2005; 59: 177–187
   PubMed Web of Science ®Google Scholar